Publications for Joy Ho
Publications for Joy Ho
2016
Bryant, C., Fromm, P., Kupresanin, F., Clark, G.,
Lee, K., Clarke, C., Silveira, P., Suen, H.,
Brown, R., Newman, E., Hart, D., et al (2016). A
CD2 high-expressing stress-resistant human
plasmacytoid dendritic-cell subset. Immunology
and Cell Biology, 94(5), 447-457. <a
href="http://dx.doi.org/10.1038/icb.2015.116">[
More Information]</a>
2015
Weber, N., Mollee, P., Augustson, B., Brown,
R., Catley, L., Gibson, J., Harrison, S., Ho, J.,
Horvath, N., Jaksic, W., et al (2015).
Management of Systemic AL Amyloidosis:
Recommendations of the Myeloma Foundation
of Australia Medical and Scientific Advisory
Group. Internal Medicine Journal, 45(4),
371-382. <a
href="http://dx.doi.org/10.1111/imj.12566">[Mo
re Information]</a>
Brown, R., Yang, S., Weatherburn, C., Gibson,
J., Ho, J., Suen, H., Hart, D., Joshua, D. (2015).
Phospho-flow detection of constitutive and
cytokine-induced pSTAT3/5, pAKT and pERK
expression highlights novel prognostic
biomarkers for patients with multiple myeloma.
Leukemia, 29(2), 483-490. <a
href="http://dx.doi.org/10.1038/leu.2014.204">[
More Information]</a>
Ho, J., Marlton, P., Tam, C., Stevenson, W.,
Ritchie, D., Bird, R., Dunlop, L., Durrant, S.,
Ross, D. (2015). Practical management of
myelofibrosis with ruxolitinib. Internal Medicine
Journal, 45(12), 1221-1230. <a
href="http://dx.doi.org/10.1111/imj.12921">[Mo
re Information]</a>
Suen, H., Brown, R., Yang, S., Ho, J., Gibson, J.,
Joshua, D. (2015). The failure of immune
checkpoint blockade in multiple myeloma with
PD-1 inhibitors in a phase 1 study. Leukemia,
29(7), 1621-1622. <a
href="http://dx.doi.org/10.1038/leu.2015.104">[
More Information]</a>
Ho, J., Marks, G., Fox, G. (2015). The impact of
sputum quality on tuberculosis diagnosis: a
systematic review. International Journal of
Tuberculosis and Lung Disease, 19(5), 537-544.
<a
href="http://dx.doi.org/10.5588/ijtld.14.0798">[
More Information]</a>
Quach, H., Joshua, D., Ho, J., Szer, J., Spencer,
A., Harrison, S., Mollee, P., Roberts, A.,
Horvath, N., Talulikar, D., Gibson, J., et al
(2015). Treatment of patients with multiple
myeloma who are eligible for stem cell
transplantation: Position statement of the
Myeloma Foundation of Australia Medical and
Scientific Advisory Group. Internal Medicine
Journal, 45(1), 94-105. <a
href="http://dx.doi.org/10.1111/imj.12640">[Mo
re Information]</a>
Quach, H., Joshua, D., Ho, J., Szer, J., Spencer,
A., Harrison, S., Mollee, P., Roberts, A.,
Horvath, N., Talaulikar, D., Gibson, J., et al
(2015). Treatment of patients with multiple
myeloma who are not eligible for stem cell
transplantation: position statement of the
myeloma foundation of Australia Medical and
Scientific Advisory Group. Internal Medicine
Journal, 45(3), 335-343. <a
href="http://dx.doi.org/10.1111/imj.12688">[Mo
re Information]</a>
Brown, R., McAuliffe, S., Catalano, A., Ho, J.,
Nassif, N., Woodland, N., Hart, D.,
Weatherburn, C., Yang, S., Suen, H., Joshua, D.,
et al (2015). Using digital polymerase chain
reaction to detect minimal residual disease in
myeloma by identifying FGFR3 up-regulation.
Leukemia & Lymphoma, 56(9), 2714-2716. <a
href="http://dx.doi.org/10.3109/10428194.2014.
1003061">[More Information]</a>
2014
Favaloro, J., Brown, R., Aklilu, E., Yang, S.,
Suen, H., Hart, D., Fromm, P., Gibson, J., Khoo,
L., Ho, J., Joshua, D. (2014). Myeloma skews
regulatory T and pro-inflammatory T helper 17
cell balance in favor of a suppressive state.
Leukemia & Lymphoma, 55(5), 1090-1098. <a
href="http://dx.doi.org/10.3109/10428194.2013.
825905">[More Information]</a>
2013
Bryant, C., Suen, H., Brown, R., Yang, S.,
Favaloro, J., Aklilu, E., Gibson, J., Ho, J., Iland,
H., Fromm, P., Hart, D., Joshua, D., et al (2013).
Long-term survival in multiple myeloma is
associated with a distinct immunological profile,
which includes proliferative cytotoxic T-cell
clones and a favourable Treg/Th17 balance.
Blood Cancer Journal, 3, 1-7. <a
href="http://dx.doi.org/10.1038/bcj.2013.34">[M
ore Information]</a>
2012
Ling, S., Lau, K., Al-Shabeeb, A., Nikolic, A.,
Catalano, A., Iland, H., Horvath, N., Ho, J.,
Harrison, S., Fleming, S., Joshua, D., Allen, J.
(2012). Response of myeloma to the proteasome
inhibitor bortezomib is correlated with the
unfolded protein response regulator XBP-1.
Haematologica, 97(1), 64-72. <a
href="http://dx.doi.org/10.3324/haematol.2011.0
43331">[More Information]</a>
Publications for Joy Ho
Ho, J., Brown, R., Spencer, A., Jeffels, M.,
Daniher, D., Gibson, J., Joshua, D. (2012).
Thalidomide consolidation improves
progression-free survival in myeloma with
normal but not up-regulated expression of
fibroblast growth factor receptor 3: analysis from
the Australasian Leukaemia and Lymphoma
Group MM6 clinical trial. Leukemia &
Lymphoma, 53(9), 1728-1734. <a
href="http://dx.doi.org/10.3109/10428194.2012.
664842">[More Information]</a>
2011
Ho, J., Tay, L., Lindeman, R., Catley, L.,
Bowden, D. (2011). Australian guidelines for the
assessment of iron overload and iron chelation in
transfusion-dependent thalassaemia major, sickle
cell disease and other congenital anaemias.
Internal Medicine Journal, 41(7), 516-524. <a
href="http://dx.doi.org/10.1111/j.1445-5994.201
1.02527.x">[More Information]</a>
Viprakasit, V., Ibrahim, H., Ha, S., Ho, J., Li, C.,
Chan, L., Chiu, C., Sutcharitchan, P., Habr, D.,
Domokos, G., et al (2011). Clinical efficacy and
safety evaluation of tailoring iron chelation
practice in thalassaemia patients from
Asia-Pacific: a subanalysis of the EPIC study of
deferasirox. International Journal of Hematology
(online), 93(3), 319-328. <a
href="http://dx.doi.org/10.1007/s12185-011-078
9-8">[More Information]</a>
2007
Loh, Y., Mo, S., Brown, R., Yamagishi, T.,
Yang, S., Joshua, D., Ho, P., Gibson, J.,
Roufogalis, B., Sze, D. (2007). Characteristics of
'side population' as the putative cancer stem cells
in myeloma: Cell growth and differentiation
capability. Molecular Cancer Therapeutics,
6(12), 3365s-3366s.
<a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=17970927">[More Information]</a>
2006
Trent, R., Webster, B., Bowden, D., Gilbert, A.,
Ho, J., Lindeman, R., Lammi, A., Rowell, J.,
Hinchcliffe, M., Colley, A., et al (2006).
Complex phenotypes in the
haemoglobinopathies: recommendations on
screening and DNA testing. Pathology, 38(6),
507-519.
Sze, D., Brown, R., Yang, S., Ho, J., Gibson, J.,
Joshua, D. (2006). The use of thalidomide in
myeloma therapy as an effective anticancer drug.
Current Cancer Drug Targets, 6(4), 325-331. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16848723">[More Information]</a>
Ling, S., Joshua, D., Gibson, J., Young, G.,
Iland, H., Watson, G., Ho, J. (2006).
Transformation and Progression of
Waldenström's Macroglobulinemia Following
Cladribine Therapy in Two Cases: Natural
Evolution or Iatrogenic Causation? American
Journal Of Hematology, 81(2), 110-114. <a
href="http://dx.doi.org/10.1002/ajh.20475">[Mo
re Information]</a>
2005
Brown, R., Ho, J. (2005). Identification of
Malignant Plasma Cells by mRNA In Situ
Hybridization. Methods in molecular medicine,
113, 175-181.
Joshua, D., Brown, R., Ho, J. (2005). Multiple
myeloma: challenges and opportunities. Methods
in molecular medicine, 113(Multiple Myeloma:
Methods and Protocols), 1-4.
Sanders, J., Crawford, B., Gibson, J., Ho, J.,
Iland, H., Joshua, D. (2007). Is there a case for
the early use of bisphosphonates in smouldering
myeloma and MGUS? (Bisphosphonates in
SMM & MGUS). International Journal of
Laboratory Hematology, 29(5), 395-397. <a
href="http://dx.doi.org/10.1111/j.1365-2257.200
6.00860.x">[More Information]</a>
Ho, J. (2005). Multiple Myeloma: Methods and
Protocols. Totowa, NJ, USA: Humana Press.
Ling, S., Campbell, L., Ho, J., Gibson, J., Joshua,
D. (2007). Molecular Biology, Pathology, and
Cytogenetics. In Mikkael A. Sekeres, Matt E.
Kalaycio, Brian J. Bolwell (Eds.), Clinical
Malignant Haematology, (pp. 847-857). United
States: McGraw Hill.
2004
Osborn, R., de Abreu Lourenço, R., Dalton, A.,
Houltram, J., Dowton, D., Joshua, D., Lindeman,
R., Ho, J. (2007). Quality of life related to oral
versus subcutaneous iron chelation: a time
trade-off study. Value in Health, 10(6), 451-456.
Gibson, J., Joshua, D., Ho, J., Campbell, L.,
Ling, S. (2005). Multiple Myeloma: molecular
biology, Pathology and Cytogenics. In Susan
Hallam, Ian Cross, Michael Thaut (Eds.), Oxford
Handbook of Music Psychology. Oxford, UK:
Oxford University Press.
Brown, R., Murray, A., Pope, B., Sze, D.,
Gibson, J., Ho, J., Joshua, D. (2004). B7+ T
Cells In Myeloma: An Acquired Marker Of Prior
Chronic Antigen Presentation. Leukemia and
Lymphoma, 45(2), 363-371.
Brown, R., Murray, A., Pope, B., Sze, D.,
Gibson, J., Ho, J., Hart, D., Joshua, D. (2004).
Either Interleukin-12 Or Interferon-γ Can
Correct The Dendritic Cell Defect Induced By
Publications for Joy Ho
Transforming Growth Factor β�? In Patients
With Myeloma. British Journal of Haematology,
125(2), 743-748.
of primary myeloma tumors, but do not relate to
known prognostic indicators or survival. Blood,
97, 490-495.
Gibson, J., Ho, J., Joshua, D. (2004). Evolving
Transplant Options For Multiple Myeloma:
Autologous And Nonmyeloablative Allogenic.
Transplantation Proceedings, 36(8), 2501-2503.
<a
href="http://dx.doi.org/10.1016/j.transproceed.20
04.06.033">[More Information]</a>
2000
Gibson, J., Ho, J., Joshua, D. (2004). Low-Grade
Lymphoma: The Optimal Timing.
Transplantation Proceedings, 36(7), 1995-1998.
<a
href="http://dx.doi.org/10.1016/j.transproceed.20
04.06.034">[More Information]</a>
Joshua, D., Gibson, J., Brown, R., Ho, J. (2004).
The Immune System In Myeloma. In Gosta
Garton, Brian Durie, Diana Samson (Eds.),
Multiple myeloma and related disorders, (pp.
29-46). UK: Hodder Arnold.
Ho, J., Gibson, J., Joshua, D. (2004). Treatment
Of Multiple Myeloma: Current Management
And New Approaches. American Journal of
Cancer, 3(1), 47-66.
2003
Sze, D., Brown, R., Yuen, E., Gibson, J., Ho, J.,
Raitakari, M., Basten, A., Joshua, D., Fazekas de
St Groth, B. (2003). Clonal Cytotoxic T Cells in
Myeloma. Leukemia and Lymphoma, 44(10),
1667-1674.
Sze, D., Brown, R., Yang, S., Gibson, J., Ho, J.,
Fazekas de St Groth, B., Basten, A., Joshua, D.
(2003). Prediction of high affinity class
I-restricted multiple myeloma idiotype peptide
epitopes. Leukemia and Lymphoma, 44(9),
1557-1568.
2002
Ho, J. (2002). Chromosomal and genetic
abnormalities in myeloma. Clinical and
Laboratory Haematology, , 259-269.
Ho, J., Gibson, J., Joshua, D., Campbell, L.,
Brown, R. (2002). The biology and cytogenetics
of multiple myeloma. Reviews in Clinical and
Experimental Hematology, 6(3), 276-300.
2001
Sze, D., Giesajtis,, G., Brown, R., Raitakari, M.,
Gibson, J., Ho, J., Baxter, A., Fazekas de St
Groth, B., Basten, A., Joshua, D. (2001). Clonal
cytotoxic T cells are expanded in myeloma and
reside in the CD8+Cd57+CD28- compartment.
Blood, 98(9), 2817-2827.
Ho, J., Basten, A., Gibson, J., Joshua, D., Brown,
R., Pelka, G. (2001). Illegitimate switch
recombinations are present in approximately half
Ho, J., Thein, S. (2000). Gene regulation and
deregulation: a beta globin perspective. Blood
Reviews, 14, 78-93.